What is Genprex, Inc. (GNPX)?
Genprex, Inc. is a clinical-stage gene therapy company focused on developing novel treatments for cancer and other serious diseases. The company specializes in the research and development of gene-based therapies that aim to restore normal cellular function by delivering therapeutic genes directly to patients' cells. Its primary areas of interest include non-small cell lung cancer and other solid tumors. Genprex's approach involves the use of proprietary gene delivery technologies designed to enhance the efficacy and safety of its therapeutic candidates. The company operates within the biotechnology sector and collaborates with various research institutions and clinical partners to advance its pipeline. Genprex's work contributes to the broader field of precision medicine, where treatments are tailored based on genetic and molecular profiles. The company also focuses on regulatory compliance and clinical trial management to ensure adherence to industry standards. Its efforts are part of ongoing advancements in gene therapy aimed at providing new options for patients with limited treatment alternatives.
Genprex, Inc. Stock Price Today: Live Overview
The price today is shaped by Genprex, Inc.'s trading dynamics, now at $2.0550. The stock has seen a daily range between $1.865 and $2.025, with a daily change of 0%.
FAQ: Genprex, Inc. (GNPX)
What is the current price of GNPX stock?
The current price stands at $2.0550.
Does GNPX pay dividends?
The company does not currently pay dividends.
Does GNPX have a formal corporate presence or regional headquarters in the UAE?
Genprex, Inc. operates via partners and distributors in the UAE without an official regional office or subsidiary.
What is GNPX best known for?
Genprex, Inc. is most famous for its development of gene therapy products for cancer treatment.
What assets are typically shown together with GNPX?
Commonly shown alongside GNPX: Lesaka Technologies Inc, Scholar Rock Holding Corp, BioXcel Therapeutics, Inc.
Latest shares articles



